Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Other Working Capital Changes (2016 - 2025)

Historic Other Working Capital Changes for Rhythm Pharmaceuticals (RYTM) over the last 10 years, with Q3 2025 value amounting to -$6.4 million.

  • Rhythm Pharmaceuticals' Other Working Capital Changes fell 612358.49% to -$6.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.3 million, marking a year-over-year increase of 27192.11%. This contributed to the annual value of $5.5 million for FY2024, which is 29207.23% up from last year.
  • According to the latest figures from Q3 2025, Rhythm Pharmaceuticals' Other Working Capital Changes is -$6.4 million, which was down 612358.49% from $6.8 million recorded in Q2 2025.
  • Rhythm Pharmaceuticals' 5-year Other Working Capital Changes high stood at $6.8 million for Q2 2025, and its period low was -$6.4 million during Q3 2025.
  • Over the past 5 years, Rhythm Pharmaceuticals' median Other Working Capital Changes value was -$101000.0 (recorded in 2022), while the average stood at $157947.4.
  • As far as peak fluctuations go, Rhythm Pharmaceuticals' Other Working Capital Changes skyrocketed by 396831.68% in 2023, and later plummeted by 612358.49% in 2025.
  • Over the past 5 years, Rhythm Pharmaceuticals' Other Working Capital Changes (Quarter) stood at $4.9 million in 2021, then crashed by 177.08% to -$3.8 million in 2022, then crashed by 37.97% to -$5.2 million in 2023, then surged by 208.81% to $5.7 million in 2024, then plummeted by 211.92% to -$6.4 million in 2025.
  • Its Other Working Capital Changes stands at -$6.4 million for Q3 2025, versus $6.8 million for Q2 2025 and $3.2 million for Q1 2025.